ArticleJournal of nanobiotechnology2026
Targeting the HIF-1α/PPARγ axis with curcumin carbon dots to combat uranium nephrotoxicity.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Uranium-induced nephrotoxicity involves complex mechanisms and lacks therapeutic interventions. This study identifies the HIF-1α/PPARγ axis as a key driver of renal lipid reprogramming and injury following uranium exposure. Using molecular docking, co-immunoprecipitation (Co-IP), ChIP-qPCR, and dual-luciferase reporter assays, we confirmed that HIF-1α directly regulates PPARγ expression and downstream lipotoxicity. The causal role of this axis was further validated using HIF-1α knockdown/knockout models and PPARγ pharmacological modulators (GW9662 and Rosi). Curcumin-derived carbon dots (CCDs) were synthesized at temperatures ranging from 120 to 210 °C. As-prepared CCDs-210 exhibited uniform size (< 10 nm), and excellent biocompatibility. Carbonization temperature governed cellular uptake: CCDs-210 entered via active endocytosis, while CCDs-120 used passive diffusion. In uranium-exposed HK-2 cells, CCDs-210 scavenged ROS, stabilized mitochondrial membrane potential, and suppressed the HIF-1α/PPARγ axis, reversing lipid dysregulation and improving cell viability. In vivo, CCDs-210 attenuated renal histopathological damage, restored renal function, and conferred multi-organ protection. These findings establish the HIF-1α/PPARγ axis as a central mediator of uranium nephrotoxicity and demonstrate that CCDs-210, by targeting this axis, effectively mitigate oxidative stress, inflammation, and lipid metabolic disruption. This work provides both a mechanistic foundation and a translatable nanotherapeutic strategy for treating uranium-induced kidney injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.